SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Pearson Robert)
 

Sökning: WFRF:(Pearson Robert) > Three Versus Six Mo...

  • Hanna, Catherine R.Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland. (författare)

Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer : A Multi-Country Cost-Effectiveness and Budget Impact Analysis

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • Elsevier,2021
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-455867
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-455867URI
  • https://doi.org/10.1016/j.clcc.2021.04.001DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • This study widens the transferability of cost-utility results from the SCOT trial showing that administering 3 months of adjuvant, oxaliplatin-based chemotherapy is cost-effective and cost saving compared to 6 months from the perspective of all countries recruited to SCOT. The impact on healthcare budgets if the findings are implemented as predicted will amount to savings of at least US$150 million over 5 years. Background: The Short Course Oncology Treatment (SCOT) trial demonstrated non-inferiority, less toxicity, and cost-effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, and the United Kingdom. Patients and Methods: Individual cost-utility analyses were performed from the perspective of each country. Resource, quality of life, and survival estimates from the SCOT trial (N = 6065) were used. Probabilistic sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost-utility analyses, the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5-year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity analysis addressed uncertainty within the budget impact analysis. Results: Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. Conclusion: This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could fully justify the investment in conducting the SCOT trial.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Robles-Zurita, Jose A.Univ Glasgow, Inst Hlth & Wellbeing, Hlth Econ & Hlth Technol Assessment, Glasgow, Lanark, Scotland. (författare)
  • Briggs, AndrewLondon Sch Hyg & Trop Med, London, England. (författare)
  • Harkin, AndreaUniv Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland. (författare)
  • Kelly, CarolineUniv Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland. (författare)
  • McQueen, JohnUniv Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland. (författare)
  • Allan, KarenUniv Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland. (författare)
  • Pearson, SarahUniv Oxford, Dept Oncol, Oncol Clin Trials Off, Oxford, England. (författare)
  • Hollander, HenrikZealand Univ Hosp, Dept Oncol, Naestved, Denmark. (författare)
  • Glimelius, BengtUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)bengglim (författare)
  • Salazar, RamonHosp Llobregat, Bellvitge Biomed Res Inst IDIBELL CIBERONC, Catalon Inst Oncol, Dept Med Oncol,Oncobell Program, Barcelona, Spain. (författare)
  • Segelov, EvaMonash Hlth, Clayton, Vic, Australia.;Monash Univ, Clayton, Vic, Australia. (författare)
  • Saunders, MarkChristie NHS Fdn Trust, Manchester, Lancs, England. (författare)
  • Iveson, TimUniv Hosp Southampton, Southampton Gen Hosp, Southampton, Hants, England. (författare)
  • Jones, Robert J.Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland. (författare)
  • Boyd, Kathleen A.Univ Glasgow, Inst Hlth & Wellbeing, Hlth Econ & Hlth Technol Assessment, Glasgow, Lanark, Scotland. (författare)
  • Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland.Univ Glasgow, Inst Hlth & Wellbeing, Hlth Econ & Hlth Technol Assessment, Glasgow, Lanark, Scotland. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Clinical colorectal cancer: Elsevier20:3, s. 236-2441533-0028

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy